Lessons Learned from SMAD4 Loss in Squamous Cell Carcinomas

Overview

Journal Mol Carcinog

Specialties Molecular Biology
Oncology

Date 2019 May 30

PMID 31140647

Citations 8

Authors

Ariel L Hernandez

Christian D Young

Jing H Wang

Xiao-Jing Wang

Affiliations

Soon will be listed here.

Abstract

SMAD4 is a potent tumor suppressor and a central mediator of the TGFß signaling pathway. SMAD4 genetic loss is frequent in squamous cell carcinomas (SCCs). Reports of SMAD4 expression in SCCs vary significantly possibly due to inter-tumor heterogeneity or technical reasons. SMAD4 loss is an initiation event for SCCs. In tumor epithelial cells, SMAD4 loss causes increased proliferation, decreased apoptosis, and "Brca-like" genomic instability associated with DNA repair defects. SMAD4 loss also plays a role in the expansion of cancer stem cells. Epithelial SMAD4 loss causes overexpression of TGFß that is released into the tumor microenvironment and contributes to SCC progression through proinflammatory and immune evasive mechanisms. SMAD4 loss, while not a direct therapeutic target, is associated with multiple targetable pathways that require further therapeutic studies. Altogether, SMAD4 loss is a potential biomarker in SCCs that should be further studied for its values in prognostic and therapeutic predictions. Such information will potentially guide future biomarker-driven clinical trial designs and improve SCC patient outcomes.

Citing Articles

MHC class I upregulation contributes to the therapeutic response to radiotherapy in combination with anti-PD-L1/anti-TGF-β in squamous cell carcinomas with enhanced CD8 T cell memory-driven response.

Lind H, Hall S, Strait A, Goon J, Aleman J, Chen S Cancer Lett. 2024; 608:217347.

PMID: 39580046 PMC: 11875078. DOI: 10.1016/j.canlet.2024.217347.

Methylation status, mRNA and protein expression of the SMAD4 gene in patients with non-melanocytic skin cancers.

Gursel Urun Y, Budak M, Usturali Keskin E Mol Biol Rep. 2023; 50(9):7295-7304.

PMID: 37428273 DOI: 10.1007/s11033-023-08656-2.

Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss.

Erasimus H, Kolnik V, Lacroix F, Sidhu S, DAgostino S, Lemaitre O Cancer Res Commun. 2023; 3(5):780-792.

PMID: 37377893 PMC: 10158796. DOI: 10.1158/2767-9764.CRC-22-0301.

Black Tea Extract, via Modulation of TGF-β Pathway, Prevents Inorganic Arsenic-induced Development of Squamous Cell Carcinoma of the Skin in Swiss Albino Mice.

Ghosh A, Roy M J Cancer Prev. 2023; 28(1):12-23.

PMID: 37033331 PMC: 10080015. DOI: 10.15430/JCP.2023.28.1.12.

Exploration of novel biomarkers in Alzheimer's disease based on four diagnostic models.

Zou C, Su L, Pan M, Chen L, Li H, Zou C Front Aging Neurosci. 2023; 15:1079433.

PMID: 36875704 PMC: 9978156. DOI: 10.3389/fnagi.2023.1079433.

References

Li W, Qiao W, Chen L, Xu X, Yang X, Li D . Squamous cell carcinoma and mammary abscess formation through squamous metaplasia in Smad4/Dpc4 conditional knockout mice. Development. 2003; 130(24):6143-53. DOI: 10.1242/dev.00820. View

Ma L, Teruya-Feldstein J, Weinberg R . Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007; 449(7163):682-8. DOI: 10.1038/nature06174. View

Houghtaling S, Timmers C, Noll M, Finegold M, Jones S, Meyn M . Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. Genes Dev. 2003; 17(16):2021-35. PMC: 196256. DOI: 10.1101/gad.1103403. View

Bornstein S, White R, Malkoski S, Oka M, Han G, Cleaver T . Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation. J Clin Invest. 2009; 119(11):3408-19. PMC: 2769185. DOI: 10.1172/JCI38854. View

Hsu D, Lan H, Huang C, Tai S, Chang S, Tsai T . Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer. Clin Cancer Res. 2010; 16(18):4561-71. DOI: 10.1158/1078-0432.CCR-10-0593. View

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

Malkoski S, Wang X . Two sides of the story? Smad4 loss in pancreatic cancer versus head-and-neck cancer. FEBS Lett. 2012; 586(14):1984-92. PMC: 3285395. DOI: 10.1016/j.febslet.2012.01.054. View

Dedes K, Wilkerson P, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho J . Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle. 2011; 10(8):1192-9. PMC: 3117132. DOI: 10.4161/cc.10.8.15273. View

Deng C, Scott F . Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation. Oncogene. 2000; 19(8):1059-64. DOI: 10.1038/sj.onc.1203269. View

10.

Iacobuzio-Donahue C, Fu B, Yachida S, Luo M, Abe H, Henderson C . DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009; 27(11):1806-13. PMC: 2668706. DOI: 10.1200/JCO.2008.17.7188. View

11.

Fukuchi M, Masuda N, Miyazaki T, Nakajima M, Osawa H, Kato H . Decreased Smad4 expression in the transforming growth factor-beta signaling pathway during progression of esophageal squamous cell carcinoma. Cancer. 2002; 95(4):737-43. DOI: 10.1002/cncr.10727. View

12.

Ziemke M, Patil T, Nolan K, Tippimanchai D, Malkoski S . Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer. Lung Cancer. 2017; 109:28-35. PMC: 5501281. DOI: 10.1016/j.lungcan.2017.04.017. View

13.

Haeger S, Thompson J, Kalra S, Cleaver T, Merrick D, Wang X . Smad4 loss promotes lung cancer formation but increases sensitivity to DNA topoisomerase inhibitors. Oncogene. 2015; 35(5):577-586. PMC: 4615192. DOI: 10.1038/onc.2015.112. View

14.

Massague J, Seoane J, Wotton D . Smad transcription factors. Genes Dev. 2005; 19(23):2783-810. DOI: 10.1101/gad.1350705. View

15.

White R, Neiman J, Reddi A, Han G, Birlea S, Mitra D . Epithelial stem cell mutations that promote squamous cell carcinoma metastasis. J Clin Invest. 2013; 123(10):4390-404. PMC: 3784525. DOI: 10.1172/JCI65856. View

16.

Yatsuoka T, Sunamura M, Furukawa T, Fukushige S, Yokoyama T, Inoue H . Association of poor prognosis with loss of 12q, 17p, and 18q, and concordant loss of 6q/17p and 12q/18q in human pancreatic ductal adenocarcinoma. Am J Gastroenterol. 2000; 95(8):2080-5. DOI: 10.1111/j.1572-0241.2000.02171.x. View

17.

Allen C, Clavijo P, Van Waes C, Chen Z . Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. Cancers (Basel). 2015; 7(4):2397-414. PMC: 4695900. DOI: 10.3390/cancers7040900. View

18.

Peinado H, Quintanilla M, Cano A . Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. J Biol Chem. 2003; 278(23):21113-23. DOI: 10.1074/jbc.M211304200. View

19.

Levy L, Hill C . Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev. 2005; 17(1-2):41-58. DOI: 10.1016/j.cytogfr.2005.09.009. View

20.

Jie H, Gildener-Leapman N, Li J, Srivastava R, Gibson S, Whiteside T . Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer. 2013; 109(10):2629-35. PMC: 3833228. DOI: 10.1038/bjc.2013.645. View